Pharm Country
Filter News
Found 131,422 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
Weeks after announcing a CEO shake-up and slightly decreased Q1 revenues, BMS plans to cut 48 staff members from its Princeton, NJ, facility. -
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
5/8/2023
Legend Biotech Corporation today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering.
-
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
5/8/2023
INOVIO presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.
-
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
5/8/2023
Krystal Biotech, Inc. today reported financial results and key operational progress updates for the first quarter ended March 31, 2023.
-
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights
5/8/2023
BioXcel Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2023, and provided an update on key strategic initiatives.
-
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
5/8/2023
Viatris Inc. (NASDAQ: VTRS) today reported strong results for the first quarter of 2023 reflecting another robust operational performance and instilling further confidence in the Company's ability to return to growth as it prepares to enter Phase 2 of its strategic plan in 2024.
-
Nephros Announces CEO Retirement and Succession Plan
5/8/2023
Nephros, Inc. today announced that Andy Astor, President and Chief Executive Officer, will retire in the coming months, and that Robert Banks will be named President and Chief Executive Officer effective on the first business day after the filing of Nephros’ Form 10-Q for the quarter ended March 31, 2023.
-
Catalent Delays Third Quarter Results and Conference Call and Provides Update on Fiscal 2023 Guidance
5/8/2023
Catalent, Inc. today announced that it will be delaying the release of its third fiscal quarter results and investor conference call, previously scheduled for Tuesday, May 9, 2023.
-
Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
5/8/2023
Insmed Incorporated today announced progress across its early-stage research programs, which will be discussed in greater detail this morning at the Company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.
-
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
5/8/2023
Eyenovia, Inc. (NASDAQ: EYEN) today announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired.
-
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
5/8/2023
Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live – jslm) a first-in-class single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
-
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
5/8/2023
Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in China.
-
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
5/8/2023
BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it has signed a clinical trial agreement with Northwell Health, New York State's largest health care provider and private employer, and Northwell’s Feinstein Institutes for Medical Research.
-
Trevena Announces Approval of OLINVYK in China
5/8/2023
Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that its partner in China, Jiangsu Nhwa, received formal approval from the National Medical Products Administration for OLINVYK.
-
Boudewijn van Lent Named President and CEO of VanDeMark Chemicals
5/8/2023
VanDeMark Chemical, Inc., a leading global producer of life science chemistries, announced the appointment of Dr. Boudewijn van Lent as President and CEO, effective immediately.
-
NYU Langone to Study Ability of Overdose Prevention Centers to Counter Unprecedented Overdose Crisis
5/8/2023
NYU Langone Health and Brown University's School of Public Health announced a grant award from the National Institute on Drug Abuse, part of the National Institutes of Health, to conduct research to measure the impact of some of the first publicly recognized overdose prevention centers in the United States, located in New York City and Providence, Rhode Island.
-
CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023
5/8/2023
CorMedix Inc. today announced that it will report its financial results for the first quarter ended March 31, 2023, after market close on Monday, May 15, 2023, and will host a corporate update conference call at 4:30pm Eastern Time.
-
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
5/8/2023
Rallybio Corporation today announced that company management will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference on Monday, May 15 at 2:30 p.m. ET in New York, NY.
-
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™
5/8/2023
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting.